Literature DB >> 25492254

Association of IL-6 and a functional polymorphism in the IL-6 gene with cardiovascular events in patients with CKD.

Belinda Spoto1, Francesco Mattace-Raso2, Eric Sijbrands2, Daniela Leonardis1, Alessandra Testa1, Anna Pisano1, Patrizia Pizzini1, Sebastiano Cutrupi1, Rosa M Parlongo1, Graziella D'Arrigo1, Giovanni Tripepi1, Francesca Mallamaci1, Carmine Zoccali3.   

Abstract

BACKGROUND AND OBJECTIVES: High serum IL-6 is a major risk factor for cardiovascular disease (CVD) in the general population. This cytokine is substantially increased in patients with CKD, but it is still unknown whether the link between IL-6 and CVD in CKD is causal in nature. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a cohort of 755 patients with stages 2-5 CKD, consecutively recruited from 22 nephrology units in southern Italy, this study assessed the relationship of serum IL-6 with history of CVD, as well as with incident cardiovascular (CV) events (mean follow up±SD, 31±10 months) and used the functional polymorphism (-174 G/C) in the promoter of the IL-6 gene to investigate whether the link between IL-6 and CV events is causal.
RESULTS: In adjusted analyses, serum IL-6 above the median value was associated with history of CVD (P<0.001) and predicted the incidence rate of CV events (hazard ratio, 1.66; 95% confidence interval [95% CI], 1.11 to 2.49; P=0.01). Patients homozygous for the risk allele (C) of the -174 G/C polymorphism had higher levels of IL-6 than did those with other genotypes (P=0.04). Homozygous CC patients more frequently had a history of CVD (odds ratio, 2.15; 95% CI, 1.15 to 4.00; P=0.02) as well as a 87% higher rate of incident CV events (hazard ratio, 1.87; 95% CI, 1.02 to 3.44; P=0.04) compared with other genotypes.
CONCLUSIONS: In patients with stages 2-5 CKD, high serum IL-6 is associated with history of CVD and predicts incident CV events. The parallel relationship with history of CVD and incident CV events of the -174 G/C polymorphism in the IL-6 gene suggests that IL-6 may be causally involved in the high CV risk in this population.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  cardiovascular; chronic kidney disease; epidemiology and outcomes; polymorphisms; risk factors

Mesh:

Substances:

Year:  2014        PMID: 25492254      PMCID: PMC4317745          DOI: 10.2215/CJN.07000714

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  47 in total

1.  In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease.

Authors:  Nancy S Jenny; Russell P Tracy; Malcolm S Ogg; Le Ahn Luong; Lewis H Kuller; Alice M Arnold; A Richey Sharrett; Steve E Humphries
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

2.  Interleukin-6 and acute coronary syndrome.

Authors:  U Ikeda; T Ito; K Shimada
Journal:  Clin Cardiol       Date:  2001-11       Impact factor: 2.882

3.  Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients.

Authors:  Madhumathi Rao; Daqing Guo; Mary C Perianayagam; Hocine Tighiouart; Bertrand L Jaber; Brian J G Pereira; Vaidyanathapuram S Balakrishnan
Journal:  Am J Kidney Dis       Date:  2005-02       Impact factor: 8.860

4.  Interleukin-6 exacerbates early atherosclerosis in mice.

Authors:  S A Huber; P Sakkinen; D Conze; N Hardin; R Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-10       Impact factor: 8.311

5.  Inflammatory markers and the risk of coronary heart disease in men and women.

Authors:  Jennifer K Pai; Tobias Pischon; Jing Ma; JoAnn E Manson; Susan E Hankinson; Kaumudi Joshipura; Gary C Curhan; Nader Rifai; Carolyn C Cannuscio; Meir J Stampfer; Eric B Rimm
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

6.  Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis.

Authors:  Bernhard Schieffer; Tina Selle; Andres Hilfiker; Denise Hilfiker-Kleiner; Karsten Grote; Uwe J F Tietge; Christian Trautwein; Maren Luchtefeld; Christian Schmittkamp; Sylvia Heeneman; Mat J A P Daemen; Helmut Drexler
Journal:  Circulation       Date:  2004-11-22       Impact factor: 29.690

Review 7.  Inflammation and atherosclerosis.

Authors:  Peter Libby; Paul M Ridker; Attilio Maseri
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

8.  Interleukin-6 promoter polymorphism modulates the effects of heavy alcohol consumption on early carotid artery atherosclerosis: the Carotid Atherosclerosis Progression Study (CAPS).

Authors:  Paula Jerrard-Dunne; Matthias Sitzer; Paul Risley; Donata A Steckel; Alexandra Buehler; Stefan von Kegler; Hugh S Markus
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

9.  Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment.

Authors:  Roberto Pecoits-Filho; Peter Bárány; Bengt Lindholm; Olof Heimbürger; Peter Stenvinkel
Journal:  Nephrol Dial Transplant       Date:  2002-09       Impact factor: 5.992

Review 10.  The paradigm of IL-6: from basic science to medicine.

Authors:  Tetsuji Naka; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Arthritis Res       Date:  2002-05-09
View more
  27 in total

1.  Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery.

Authors:  William R Zhang; Amit X Garg; Steven G Coca; Philip J Devereaux; John Eikelboom; Peter Kavsak; Eric McArthur; Heather Thiessen-Philbrook; Colleen Shortt; Michael Shlipak; Richard Whitlock; Chirag R Parikh
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 2.  The systemic nature of CKD.

Authors:  Carmine Zoccali; Raymond Vanholder; Ziad A Massy; Alberto Ortiz; Pantelis Sarafidis; Friedo W Dekker; Danilo Fliser; Denis Fouque; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Gianfranco Parati; Patrick Rossignol; Andrzej Wiecek; Gerard London
Journal:  Nat Rev Nephrol       Date:  2017-04-24       Impact factor: 28.314

3.  Low Plasma Testosterone Is Associated With Elevated Cardiovascular Disease Biomarkers.

Authors:  Alexander W Pastuszak; Taylor P Kohn; Joel Estis; Larry I Lipshultz
Journal:  J Sex Med       Date:  2017-07-27       Impact factor: 3.802

4.  Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

Authors:  Lene Ryom; Jens D Lundgren; Mike Ross; Ole Kirk; Matthew Law; Philippe Morlat; Eric Fontas; Colette Smit; Christoph A Fux; Camilla I Hatleberg; Stéphane de Wit; Caroline A Sabin; Amanda Mocroft
Journal:  J Infect Dis       Date:  2016-08-02       Impact factor: 5.226

5.  Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.

Authors:  Jair Munoz Mendoza; Tamara Isakova; Xuan Cai; Liz Y Bayes; Christian Faul; Julia J Scialla; James P Lash; Jing Chen; Jiang He; Sankar Navaneethan; Lavinia Negrea; Sylvia E Rosas; Matthias Kretzler; Lisa Nessel; Dawei Xie; Amanda Hyre Anderson; Dominic S Raj; Myles Wolf
Journal:  Kidney Int       Date:  2016-12-22       Impact factor: 10.612

6.  Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD.

Authors:  Jia Sun; Jonas Axelsson; Anna Machowska; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Karin Lindström; Peter Stenvinkel; Abdul Rashid Qureshi
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-08       Impact factor: 8.237

7.  Prognostic Factors of Fatal and Nonfatal Cardiovascular Events in Patients With Type 2 Diabetes: The Role of Renal Function Biomarkers.

Authors:  Stefanos Roumeliotis; Vassilios Liakopoulos; Athanasios Roumeliotis; Aikaterini Stamou; Stylianos Panagoutsos; Graziella D'Arrigo; Giovanni Tripepi
Journal:  Clin Diabetes       Date:  2021-04

8.  Application of regularized regression to identify novel predictors of mortality in a cohort of hemodialysis patients.

Authors:  Stanislas Werfel; Georg Lorenz; Bernhard Haller; Roman Günthner; Julia Matschkal; Matthias C Braunisch; Carolin Schaller; Peter Gundel; Stephan Kemmner; Salim S Hayek; Christian Nusshag; Jochen Reiser; Philipp Moog; Uwe Heemann; Christoph Schmaderer
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

9.  Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.

Authors:  Yeonhee Lee; Myoung-Jin Jang; Junseok Jeon; Jung Eun Lee; Wooseong Huh; Bum Soon Choi; Cheol Whee Park; Ho Jun Chin; Chae Lin Kang; Dong Ki Kim; Seung Seok Han; Kwon Wook Joo
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

10.  Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis.

Authors:  Susana Rocha; Maria João Valente; Susana Coimbra; Cristina Catarino; Petronila Rocha-Pereira; José Gerardo Oliveira; José Madureira; João Carlos Fernandes; Maria do Sameiro-Faria; Vasco Miranda; Luís Belo; Alice Santos-Silva; Elsa Bronze-da-Rocha
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.